Status:
COMPLETED
Quantitative COVID-19 SARS-CoV-2 Antibody Pre and Post Cardiopulmonary Bypass
Lead Sponsor:
Thomas Jefferson University
Conditions:
Laboratory Assessment SARS-CoV-2 Antibody Levels Before and After Surgery for Patients Requiring Cardiopulmonary Bypass
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to compare the levels of SARS-CoV-2 antibody prior to cardiopulmonary bypass and after cardiopulmonary bypass (CPB).
Detailed Description
This study is designed to compare the levels of SARS-CoV-2 antibody prior to cardiopulmonary bypass and after cardiopulmonary bypass (CPB). During CPB the patients' blood volume is removed from the b...
Eligibility Criteria
Inclusion
- All patients presenting for elective cardiac surgery with the use of cardiopulmonary bypass that have received 2 or 3 doses of FDA approved or Emergency Use Authorization Covid vaccine.
Exclusion
- Age \< 18.
- Patients with indeterminant history of vaccination schedule.
Key Trial Info
Start Date :
November 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 17 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05357885
Start Date
November 17 2021
End Date
March 17 2022
Last Update
May 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107